Evaluating the Impact of Oleocanthal and Oleacein on Skin Aging: Results of a Randomized Clinical Study.

The prevalence of skin aging and the request for effective treatments have driven dermatological research towards natural solutions. This study investigates the anti-aging efficacy of two bioactive natural polyphenols, Oleocanthal and Oleacein, in a skincare formulation. A single-blind, randomized clinical trial involved 70 participants, using a comprehensive exclusion criterion to ensure participant safety and study integrity. Participants applied the Oleocanthal and Oleacein 1% serum formulation twice daily for 30 days. The efficacy was objectively assessed using the VISIA® Skin Analysis System at baseline, after 15 days, and after 30 days. Results indicated significant wrinkle reduction in most groups. For women aged 45-79 years, the mean change was -33.91% (95% CI: -46.75% to -21.07%). For men aged 20-44 years, it was -51.93% (95% CI: -76.54% to -27.33%), and for men aged 45-79 years, it was -46.56% (95% CI: -58.32% to -34.81%). For women aged 20-44 years, the change was -25.68% (95% CI: -63.91% to 12.54%), not statistically significant. These findings highlight the potential of EVOO-derived polyphenols in anti-aging skincare, particularly for older adults. This research paves the way for further exploration into natural compounds in dermatology, particularly for aging skin management.

Superiority of a vitamin B12-barrier cream compared with standard glycerol-petrolatum-based emollient cream in the treatment of atopic dermatitis: A randomized, left-to-right comparative trial.

Atopic dermatitis (AD) is a result of complex genetic, epigenetic, environmental, and immunological interactions with an overlapping epidermal barrier defect. The study evaluates the efficacy and tolerability of topical Vitamin B12-barrier cream (MB12) compared with standard glycerol-petrolatum-based emollient cream (GPC) used three times a day for mild AD. The study was conducted as a on one hemi-body randomized, controlled, single-blind, intra-patient left-to-right comparative trial by patients with clinical diagnosis of mild AD measured with total SCORAD index over 4 months. MB12 was compared on one hemi-body treated (GPC). The comparisons of score values were performed primarily by using non-parametric procedures: Mann-Whitney-U test (for independent samples) and Wilcoxon test (for dependent samples). All 22 patients were randomized (left or right side treated with MB12 or GPC). At week 12 a reduction from baseline in SCORAD index was assessed in both body sites with 77.6% SCORAD index reduction in the MB12 treated body sites versus 33.5% in the GPC treated body sites. These results suggest that MB12 could represent a new option in the treatment of mild AD.

Diagnosis and treatment of refractory asthma.

Asthma is an inflammatory disorder of the airway associated with airflow obstruction and bronchial hyperresponsiveness that varies in severity across the spectrum of the disease. Asthma affects 5-7% of the population of North America and Europe, and the prevalence is increasing. Most patients with asthma are easily diagnosed, responding to standard treatment with a short-acting inhaled beta2-agonists for symptom control, and to long-term therapy to including inhaled glucocorticosteroids to control airway inflammation. However a subgroup of patients with asthma (likely approximately 10%) have more troublesome disease reflected by high medication requirements to maintain good disease control or persistent symptoms, asthma exacerbations, or airflow obstruction despite high medication use. A term to describe this subgroup of asthmatic patients is "Refractory Asthma". Patients with difficult to control asthma require a rigorous and systematic approach to their diagnosis and treatment. It is critical to make a diagnosis of asthma and to exclude other airways diseases and to identify whether there are any correctable factors that may contribute to their poor control. Another poor adherence to therapy is common reason for a poor response. Treatment involves optimizing corticosteroid inhaled therapy, assesing additional controllers, such as inhaled beta2-agonist, leukotriene inhibitors, anti-immunoglobulins (Ig), oral corticosteroids and sustained-release theophylline.

Bedside insertion of inferior vena cava filters.

Certain types of injuries make a patient more at risk for the development of a DVT or PE. Because the condition of such patients is critical, the treatment options are limited, and special attention is required so as not to cause further harm. Bedside procedures that preclude the need to transport a patient to another department offer clear advantages. By describing a tested clinical procedure--percutaneous insertion of the IVC filter--trauma nurses can gain a better understanding of how to prepare the patient, expedite the process, and provide ongoing nursing management.

Use of pelvic stabilizers.

Pelvic fractures can be devastating injuries that pose an immediate threat to life and a need for prolonged rehabilitation. The pelvic stabilizer can be used in the resuscitation phase to control hemorrhage, stabilize fractures, and allow more time to provide definitive care. Eventually the success of long-term rehabilitation will be affected by the incidence and severity of complications associated with excessive blood loss and the problem associated with an injured pelvis.